|
Match
|
Document |
Document Title |
|
|
US20170166903 |
INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
The present invention generally relates to methods and compositions used for the spatial and temporal control of gene expression that may use inducible transcriptional effectors. The invention... |
|
|
US20160083710 |
COMPOSITIONS AND METHODS COMPRISING PROTEASE VARIANTS
The present invention provides protease variants, compositions comprising protease variants, and methods of using such protease variants and compositions. |
|
|
US20160017351 |
Methods and Compositions for Targeting Sequences of Interest to the Chloroplast
Chimeric polynucleotides comprising a nucleotide sequence encoding a chloroplast transit peptide operably linked to a heterologous polynucleotide of interest are provided, wherein the chloroplast... |
|
|
US20150291966 |
INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
The present invention generally relates to methods and compositions used for the spatial and temporal control of gene expression that may use inducible transcriptional effectors. The invention... |
|
|
US20150020223 |
DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery... |
|
|
US20140315985 |
COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS
This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. |
|
|
US20140199767 |
USE
The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof. |
|
|
US20140189896 |
CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one... |
|
|
US20140115729 |
APOPTOTIC ANTI-IGE ANTIBODIES
The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. |
|
|
US20140010861 |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. |
|
|
US20130243759 |
Transgenic Animals
The present invention relates inter alia to fertile non-human vertebrates such as mice and rats useful for producing antibodies bearing human variable regions, in which endogenous antibody chain... |
|
|
US20130177561 |
THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal. |
|
|
US20120029058 |
Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. |
|
|
US20110318301 |
IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F... |
|
|
US20110250342 |
PUFA Polyketide Synthase Systems and Uses Thereof
Disclosed are the complete polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems from Schizochytrium, and biologically active fragments and homologues thereof. More particularly,... |
|
|
US20110014612 |
POLYMERASE COMPOSITIONS & METHODS
Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of... |
|
|
US20100104531 |
HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine... |
|
|
US20100016241 |
METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met... |
|
|
US20090228998 |
Induction of exon skipping in eukaryotic cells
The present invention provides a method for at least in part decreasing the production of an aberrant protein in a cell, the cell comprising pre-mRNA comprising exons coding for the protein, by... |
|
|
US20090205064 |
Mutated Acetohydroxyacid Synthase Genes in Brassica
Provided are mutated acetohydroxyacid synthase (AHAS) nucleic acids and the proteins encoded by the mutated nucleic acids. Also provided are canola plants, cells, and seeds comprising the mutated... |
|
|
US20090042266 |
TREATMENT OF CELLULOSIC MATERIAL AND ENZYMES USEFUL THERERIN
The present invention relates to the production of sugar hydrolysates from cellulosic material. The method may be used e.g. for producing fermentable sugars for the production of bioethanol from... |
|
|
US20080176285 |
GLCNAC PHOSPHOTRANSFERASE OF THE LYSOSOMAL TARGETING PATHWAY
The present invention provides nucleotide and amino sequences of the lysosomal targeting pathway enzyme GlcNAc-phosphotransferase, methods of producing and methods of purifying this enzyme. |
|
|
US20080032336 |
Chemokine receptor materials and methods
The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also... |
|
|
US20070184530 |
Long-acting veterinary polypeptides and methods of producing and administering same
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical... |
|
|
US20070098707 |
Methods and Compositions for Inhibiting C-MET Dimerization and Activation
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met... |
|
|
US20050014240 |
Aggregate-free protein compositions and methods of preparing same
A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by... |
|
|
US20050009166 |
Cellulase variants
The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a.... |
|
|
US20160194371 |
Fusion proteins comprising FGF-21 and GLP-1R agonist
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to... |
|
|
US20160186152 |
MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOF
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated... |
|
|
US20160176939 |
CANCER ANTIGEN HELPER PEPTIDE
The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding... |
|
|
US20160168589 |
METABOLICALLY ACTIVATED RECOMBINANT VIRAL VECTORS AND METHODS FOR THEIR PREPARATION AND USE
Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction... |
|
|
US20160168552 |
CELLULASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM
This invention relates to molecular and cellular biology and biochemistry. In one aspect, the invention provides polypeptides having cellulase activity, e.g., endoglucanase, cellobiohydrolase,... |
|
|
US20160159923 |
ANTIBODIES TO MATRIX METALLOPROTEINASE 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9... |
|
|
US20160159921 |
ANTIBODIES WITH ENHANCED OR SUPPRESSED EFFECTOR FUNCTION
Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc... |
|
|
US20160152707 |
CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon (CD3ε) chain and a second... |
|
|
US20160152687 |
ALBUMIN FUSION PROTEINS
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors... |
|
|
US20160145354 |
BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to... |
|
|
US20160096894 |
ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The... |
|
|
US20160090407 |
INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF
The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins,... |
|
|
US20160076055 |
LENTIVIRAL VECTORS PSEUDOTYPED WITH A SINDBIS VIRUS ENVELOPE GLYCOPROTEIN
Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle... |
|
|
US20160060345 |
Novel EGFR-Binding Molecules and Immunoconjugates Thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as... |
|
|
US20160052986 |
HUMANIZED IL-7 RODENTS
Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that... |
|
|
US20160046913 |
Modified Phosphatases
The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of... |
|
|
US20160010072 |
PROTEASES COMPRISING ONE OR MORE COMBINABLE MUTATIONS
The present invention provides engineered protease variants. In particular, the protease variants comprise combinable mutations at selected surface positions that affect the charge and/or... |
|
|
US20160009805 |
ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same. |
|
|
US20150361428 |
EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described. |
|
|
US20150361424 |
INDUCTION OF EXON SKIPPING IN EUKARYOTIC CELLS
The present invention provides a method for at least in part decreasing the production of an aberrant protein in a cell, the cell comprising pre-mRNA comprising exons coding for the protein, by... |
|
|
US20150344912 |
COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF
The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic... |
|
|
US20150344584 |
Modified Antigen Binding Molecules With Altered Cell Signaling Activity
The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including... |
|
|
US20150344576 |
HUMAN ANTI-KIR ANTIBODIES
Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a... |